ECSP034600A - Compuestos de lactama - Google Patents

Compuestos de lactama

Info

Publication number
ECSP034600A
ECSP034600A EC2003004600A ECSP034600A ECSP034600A EC SP034600 A ECSP034600 A EC SP034600A EC 2003004600 A EC2003004600 A EC 2003004600A EC SP034600 A ECSP034600 A EC SP034600A EC SP034600 A ECSP034600 A EC SP034600A
Authority
EC
Ecuador
Prior art keywords
lactama
compounds
alaninyl
methylbutyryl
benzazepin
Prior art date
Application number
EC2003004600A
Other languages
English (en)
Inventor
Varghese John
Eugene D Thorsett
Jeffrey Nissen
Lee H Latimer
James E Audia
Jay S Tung
Stacey Leigh Mcdaniel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP034600A publication Critical patent/ECSP034600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona el compuesto (N)- (S)-2-hidroxi-3- metilbutiril)-1- (l-alaninil) -(S)- 1-amino-3-metil-4, 5, 6, 7- tetrahidro-2H-3-benzazepin-2-ona.
EC2003004600A 2000-11-17 2003-05-13 Compuestos de lactama ECSP034600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17

Publications (1)

Publication Number Publication Date
ECSP034600A true ECSP034600A (es) 2003-06-25

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004600A ECSP034600A (es) 2000-11-17 2003-05-13 Compuestos de lactama

Country Status (33)

Country Link
US (1) US20050261495A1 (es)
EP (1) EP1341531B1 (es)
JP (1) JP4116437B2 (es)
KR (1) KR100819679B1 (es)
CN (1) CN1486184A (es)
AR (1) AR035927A1 (es)
AU (2) AU2002243192B2 (es)
BR (1) BR0115427A (es)
CA (1) CA2427227C (es)
CY (1) CY1106366T1 (es)
CZ (1) CZ20031351A3 (es)
DE (1) DE60126132T2 (es)
DK (1) DK1341531T3 (es)
DZ (1) DZ3453A1 (es)
EA (1) EA005954B1 (es)
EC (1) ECSP034600A (es)
ES (1) ES2278804T3 (es)
HR (1) HRP20030383B1 (es)
HU (1) HU228117B1 (es)
IL (2) IL155960A0 (es)
MX (1) MXPA03004292A (es)
MY (1) MY134559A (es)
NO (1) NO324324B1 (es)
NZ (1) NZ525854A (es)
PE (1) PE20020802A1 (es)
PL (1) PL212199B1 (es)
PT (1) PT1341531E (es)
SI (1) SI1341531T1 (es)
SK (1) SK288065B6 (es)
TW (1) TWI305204B (es)
UA (1) UA74849C2 (es)
WO (1) WO2002047671A2 (es)
ZA (1) ZA200303789B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
AU2006234441B2 (en) 2005-04-08 2011-07-07 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
WO2007088878A1 (ja) 2006-01-31 2007-08-09 Api Corporation ベンゾアゼピノン類の製造方法
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
CL2008002060A1 (es) * 2007-07-16 2008-11-21 Wyeth Corp Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
AU2008287124B2 (en) 2007-08-14 2013-06-06 Eli Lilly And Company Azepine derivatives as gamma-secretase inhibitors
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
BRPI0821090B8 (pt) 2007-12-21 2021-05-25 Ligand Pharm Inc moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
EP2892523B1 (en) 2012-09-07 2019-05-01 Massachusetts Eye & Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
AU2013312358B2 (en) 2012-09-07 2018-08-09 Massachusetts Eye & Ear Infirmary Treating hearing loss
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP2987496B1 (en) 2013-04-19 2018-08-08 National University Corporation Okayama University Treatment agent for cognitive disorders, induced by amyloid -protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
AU2017268078B2 (en) 2016-05-16 2023-03-02 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3743057A4 (en) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary TREATMENT OF HEARING LOSS
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12552826B2 (en) 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3956309A4 (en) 2019-04-19 2023-06-07 Ligand Pharmaceuticals Inc. CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP4076459A4 (en) 2019-12-17 2023-12-20 Merck Sharp & Dohme LLC Prmt5 inhibitors
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
WO2021126732A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
AU2023336062A1 (en) 2022-09-02 2025-03-13 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
AU2023397331A1 (en) 2022-12-14 2025-06-26 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002100B1 (ru) * 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO2001034571A1 (en) * 1999-11-09 2001-05-17 Eli Lilly And Company β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
JP2005538031A (ja) * 2000-11-17 2005-12-15 イーライ・リリー・アンド・カンパニー ラクタム化合物
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition

Also Published As

Publication number Publication date
MY134559A (en) 2007-12-31
PT1341531E (pt) 2007-04-30
SI1341531T1 (sl) 2007-06-30
ES2278804T3 (es) 2007-08-16
UA74849C2 (en) 2006-02-15
EA005954B1 (ru) 2005-08-25
TWI305204B (en) 2009-01-11
IL155960A (en) 2009-06-15
HUP0301842A3 (en) 2010-03-29
CA2427227A1 (en) 2002-06-20
AU4319202A (en) 2002-06-24
CA2427227C (en) 2010-08-17
WO2002047671A3 (en) 2003-03-06
DZ3453A1 (fr) 2002-06-20
ZA200303789B (en) 2004-08-16
KR100819679B1 (ko) 2008-04-04
EP1341531B1 (en) 2007-01-17
SK5592003A3 (en) 2003-12-02
JP2004517090A (ja) 2004-06-10
MXPA03004292A (es) 2004-02-12
CZ20031351A3 (cs) 2003-11-12
SK288065B6 (sk) 2013-04-03
HUP0301842A2 (hu) 2003-09-29
HU228117B1 (en) 2012-11-28
JP4116437B2 (ja) 2008-07-09
CN1486184A (zh) 2004-03-31
HK1059731A1 (en) 2004-07-16
DK1341531T3 (da) 2007-05-14
NO20032236D0 (no) 2003-05-16
KR20030051846A (ko) 2003-06-25
PL212199B1 (pl) 2012-08-31
WO2002047671A2 (en) 2002-06-20
HRP20030383B1 (hr) 2007-12-31
DE60126132D1 (de) 2007-03-08
AR035927A1 (es) 2004-07-28
NO20032236L (no) 2003-07-10
EP1341531A2 (en) 2003-09-10
IL155960A0 (en) 2003-12-23
AU2002243192B2 (en) 2006-07-20
HRP20030383A2 (en) 2005-10-31
NO324324B1 (no) 2007-09-24
DE60126132T2 (de) 2007-10-18
NZ525854A (en) 2004-06-25
CY1106366T1 (el) 2011-10-12
PL362688A1 (en) 2004-11-02
US20050261495A1 (en) 2005-11-24
EA200300580A1 (ru) 2003-10-30
PE20020802A1 (es) 2002-09-10
BR0115427A (pt) 2003-10-07

Similar Documents

Publication Publication Date Title
ECSP034600A (es) Compuestos de lactama
HN1999000154A (es) 1,2,3,4 tetrahidroquinolinas 2 sustituidas 4 - carboxiamino sustituidas.
NO20053246D0 (no) Kondensert 1,3-dihydroimidazol-ringforbindelse.
DE60135387D1 (de) 7,9 substituierte tetracyclinverbindungen
MY126559A (en) Fungicidal 2-methoxybenzophenones
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
DE60225341D1 (de) Neue 1,2,4-triazolverbindung
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
CY1106682T1 (el) Ενωση λακταμης
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
PT1389213E (pt) Formulacoes de 3,7-diazabiciclo 3,3,1¿ como compostos antiarritmicos
AR028248A1 (es) Nuevos compuestos 2,3,4,5-tetrahidro-1h-(1,4) diazepino (1,7-a) indol
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
TR199901017A2 (xx) B�cek ilac� terkibi.
EA200100854A1 (ru) Кальций-литические соединения
GB9918429D0 (en) Organic compounds
MXPA03009315A (es) 1.3-dionas carbociclicas tiazolil-substituidas como agentes pesticidas.
DK1073447T3 (da) N1-modificerede glycopeptider
BR0205298B1 (pt) máquina de semeadura.
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ITTO20020747A1 (it) Composizione.
DK1497256T3 (da) Substituerede 1,5-diaminopentan-3-ol-forbindelser
ITTO20020745A1 (it) Composizione.
IT1303333B1 (it) Sottopiede per calzature.
ATE478155T1 (de) Glycopeptidantibiotika